The Sunshine Reporter

DelveInsight Business Research LLP

DelveInsight’s “Pheochromocytoma Market Insights, Epidemiology, and Market Forecast-2032“ report delivers an in-depth understanding of the Pheochromocytoma Market  epidemiology insights, Pheochromocytoma market trends, therapies, and key companies working in the Pheochromocytoma Market in the 7MM.

Pheochromocytoma  Overview

Pheochromocytoma is a rare tumor of the adrenal medulla composed of chromaffin cells, also known as pheochromocytes. When a tumor composed of the same cells as a pheochromocytoma develops outside the adrenal gland, it is referred to as a paraganglioma. These neuroendocrine tumors typically release massive amounts of catecholamines, metanephrines, or methoxetamine, which result in the most common symptoms, including hypertension (high blood pressure), tachycardia (fast heart rate), and diaphoresis (sweating).[ Rarely, some tumors (especially paragangliomas) may secrete little to no catecholamines, making diagnosis difficult. While tumors of the head and neck are parasympathetic, their sympathetic counterparts are predominantly located in the abdomen and pelvis, particularly concentrated at the organ of Zuckerkandl.

Pheochromocytoma Epidemiology Insights

The overall incidence of pheochromocytoma or paraganglioma was 0.66 cases per 100 000 people per year. The frequency of pheochromocytoma and paraganglioma increased with age and was highest in individuals aged 60–79 years (8.85 and 14.68 cases per 100 000 people per year for males and females, 

Click here to learn more about the Pheochromocytoma Market Landscape

The Report Covers the Pheochromocytoma Epidemiology Segmented by:

• Pheochromocytoma prevalent cases 

• Pheochromocytoma diagnosed cases 

• Pheochromocytoma treatment cases 

• Pheochromocytoma incident cases 

Pheochromocytoma Market Outlook 

The Pheochromocytoma market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Pheochromocytoma market trends by analyzing the impact of current Pheochromocytoma therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Pheochromocytoma market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Pheochromocytoma market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Pheochromocytoma market in 7MM is expected to witness a major change in the study period 2019-2032.

Key Companies Working in the Pheochromocytoma Market:

• Molecular Insight Pharmaceuticals 

• Pfizer 

• Merck Pharmaceuticals 

• GE Healthcare Pharmaceuticals 

And many others 

Pheochromocytoma Therapies Covered and Analyzed in the Report:

•  123I-mIBG

• Ultratrace Iobenguane

• Axitinib

• Sunitinib

And many others 

Learn more about the Key Companies and Emerging Therapies in the Pheochromocytoma  Market

Table of Contents 

1. Key Insights 

2. Pheochromocytoma  Introduction 

3. Executive Summary of Pheochromocytoma         

4. Disease Background and Overview

5. Epidemiology and patient population

6. Pheochromocytoma  Emerging Therapies

7. Pheochromocytoma  Market Outlook

8. Market Access and Reimbursement of Therapies

9. Market Drivers 

10. Market Barriers 

11. Appendix

12. Report Methodology

13. DelveInsight Capabilities

14. Disclaimer

Learn about the detailed offerings of the report @ Pheochromocytoma Market Outlook

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services